Aarkstore.com announces, a new market research report is available in its vast collection Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues http://www.aarkstore.com/reports/Generic-Growth-Strategies-Manufacturers-to-Increase-Focus-on-Super-Generics-and-Biosimilars-to-Drive-Revenues-128803.html Summary Company has released its research “Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues”. It provides a comprehensive overview of the generic drugs market, analysis of upcoming noteworthy patent expirations, and trends and issues facing the generics market. The report delves into much detail on the current landscape; changes that have structured the generic drugs market in the last 30 years; and the reason behind the players’ urgency in developing and implementing generic growth strategies. The report also contains impact analysis of the regulatory landscape in the major geographies pertaining to the generic drugs market. Major strategies adopted by the leading companies in the generic drugs market have been analyzed in much detail, along with an elaborate company portfolio and strategic analysis of leading generic players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts. Company has found that the pharmaceutical industry in general and the generics sector in particular have turned out to be highly competitive of late. Scope The scope of this report includes - - Detailed study of generic growth strategies with special emphasis on strategies which help in combating intensive competition. - Analysis of the major strategies adopted by companies looking to expand geographical reach. - Case studies of successful generic growth strategies. - Competitive profiling of leading companies. The key companies studied in this report are Teva, Sandoz, Hospira, Watson, Mylan, Perrigo, STADA, DRL, Par, Apotex and Actavis. Reasons to buy The report will enhance your decision making capability. It will allow you to - - Build understanding of the key generic growth strategies in place and the trends in the market - Optimize your R&D pipeline through identification and understanding of the key strategy for your drug. - Identify the key players best positioned to capitalize on their products through effective management of their patented products. - Develop effective business strategies related to generic drugs through the analytical insight gained from case studies covering different strategies in the market. Table of Contents : 1.1 List of Tables 5 1.2 List of Figures 5 2 Generic Growth Strategies: Introduction 6 2.1 Company Report Guidance 7 3 Generic Growth Strategies: Market Overview 8 3.1 Overview of the Generics Market 8 3.2 Patent Expiries – Peak Years 8 3.3 Patent Expiration of Blockbuster Drugs, By Therapeu

1. Aarkstore.com announces, a new market research report is available in its vast collection
Generic Growth Strategies - Manufacturers to Increase Focus
on Super Generics and Biosimilars to Drive Revenues
http://www.aarkstore.com/reports/Generic-Growth-Strategies-Manufacturers-to-Increase-Focus-on-
Super-Generics-and-Biosimilars-to-Drive-Revenues-128803.html
Summary
Company has released its research “Generic Growth Strategies - Manufacturers to
Increase Focus on Super Generics and Biosimilars to Drive Revenues”. It provides a
comprehensive overview of the generic drugs market, analysis of upcoming
noteworthy patent expirations, and trends and issues facing the generics market.
The report delves into much detail on the current landscape; changes that have
structured the generic drugs market in the last 30 years; and the reason behind the
players’ urgency in developing and implementing generic growth strategies. The
report also contains impact analysis of the regulatory landscape in the major
geographies pertaining to the generic drugs market. Major strategies adopted by
the leading companies in the generic drugs market have been analyzed in much
detail, along with an elaborate company portfolio and strategic analysis of leading
generic players. This report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house analysis by
Company’s team of industry experts. Company has found that the pharmaceutical
industry in general and the generics sector in particular have turned out to be
highly competitive of late.
Scope
The scope of this report includes -
- Detailed study of generic growth strategies with special emphasis on strategies
which help in combating intensive competition.
- Analysis of the major strategies adopted by companies looking to expand
geographical reach.

2. - Case studies of successful generic growth strategies.
- Competitive profiling of leading companies. The key companies studied in this
report are Teva, Sandoz, Hospira, Watson, Mylan, Perrigo, STADA, DRL, Par,
Apotex and Actavis.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Build understanding of the key generic growth strategies in place and the trends
in the market
- Optimize your R&D pipeline through identification and understanding of the key
strategy for your drug.
- Identify the key players best positioned to capitalize on their products through
effective management of their patented products.
- Develop effective business strategies related to generic drugs through the
analytical insight gained from case studies covering different strategies in the
market.
Table of Contents :
1.1 List of Tables 5
1.2 List of Figures 5
2 Generic Growth Strategies: Introduction 6
2.1 Company Report Guidance 7
3 Generic Growth Strategies: Market Overview 8
3.1 Overview of the Generics Market 8
3.2 Patent Expiries – Peak Years 8
3.3 Patent Expiration of Blockbuster Drugs, By Therapeutic Area 10
3.4 Upcoming Patent Expiries 11
3.5 Trends and Issues 11
3.5.1 ANDA Filings and Approvals are on the Rise 11
3.5.2 European Market for Small Molecule Generic Drugs versus Biosimilars 13
3.5.3 Untapped Generics Market in Certain European Countries 14

3. 3.5.4 Biosimilars Focus – Innovators as Well as Generics Companies 15
3.5.5 Drop in Patent Applications by Top Innovator Companies a Cause of Worry for
Generics 16
3.5.6 Evergreening Strategies Pose an Issue 17
3.5.7 Market Forces in the European Union 17
4 Generic Growth Strategies: Current Generic Landscape 19
4.1 Generic Industry Structure 19
For More details Plz do contact :
Aarkstore Enterprise
Phone:08149852585
Email: enquiry@aarkstore.com
URL:www.aarkstore.com
Our Website :www.aarkstore.com
Facebook: http://www.facebook.com/aarkstore
Linkedin: http://in.linkedin.com/in/aarkstore